2.3. Prognosis Before the caplacizumab era, the mortality rate of the first iTTP episode was ~4% in children [13,21,25]. These epidemiological data need to be updated in the coming years. Disease relapse is recognized as a risk in iTTP. Child-onset iTTP requires a long-term follow-up to avoid a clinical relapse that is preventable by preemptive rituximab injections when the ADAMTS13 activity drops below 10 IU/dL [7,13,27].
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Adrien
Contact Adrien, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack